WH COVID Response Coordinator: J&J Pause Won’t Have ‘Significant Impact’ On Vaccine Rollout

Jeff Zients, President-elect Joe Biden’s pick to head the White House’s coronavirus response, speaks during a news conference at the Queen Theater on December 8, 2020 in Wilmington, Delaware. (Photo by Chip Somod... Jeff Zients, President-elect Joe Biden’s pick to head the White House’s coronavirus response, speaks during a news conference at the Queen Theater on December 8, 2020 in Wilmington, Delaware. (Photo by Chip Somodevilla/Getty Images) MORE LESS
|
April 13, 2021 11:28 a.m.

White House COVID-19 Response Coordinator Jeff Zients said on Tuesday that federal health agencies’ recommendation to pause Johnson & Johnson’s COVID-19 vaccine would not cause a major disruption to the Biden administration’s vaccine rollout program.

“This announcement will not have a significant impact on our vaccination plan: Johnson & Johnson vaccine makes up less than 5 percent of the recorded shots in arms in the United States to date,” Zients said in a statement.

The official stated that the 300 million doses of Pfizer and Moderna’s vaccines secured by President Joe Biden meant there was “more than enough supply to continue the current pace of vaccinations of 3 million shots per day, and meet the President’s goal of 200 million shots by his 100th day in office.”

Earlier on Tuesday, the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) released a joint recommendation advising health care providers to stop administering J&J’s vaccine “out of an abundance of caution” while the agencies investigate the six reported cases of blood clots after the patients received the vaccine.

Newsletters
Get TPM in your inbox, twice weekly.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

The agencies noted that the clots “appear to be extremely rare.”

During the FDA and CDC’s press conference on their announcement, acting FDA Commissioner Janet Woodcock said the pause was expected to last for “a matter of days.”

Shortly after the FDA and CDC made the recommendation, several states announced they would cease the distribution of J&J’s vaccine.

The pharmaceutical company said on Tuesday that it was “aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine.”

Latest News
Comments are now Members-Only

Non-members are still able to read comments, but will no longer be able to participate. To join the conversation, sign up now and get:

30% Off Annual Prime Membership

TPM strives to build as inclusive a community as financially possible. We offer FREE memberships to those experiencing financial hardship and FREE memberships for students.

View all options
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriters:
Audience Development Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: